TABLE 2.

The CAMARADES quality items.

Study	①	②	③	④	⑤	⑥	⑦	⑧	⑨	⑩	Quality score
He et al. (2020)	√	√	√	N	N	N	√	?	N	√	5
Liao (2020)	√	√	√	N	N	N	√	√	√	√	7
Liao et al. (2019)	√	√	√	N	N	N	√	√	N	√	6
Mei et al. (2010)	√	√	√	N	N	N	√	√	N	√	6
Wan (2022)	√	√	√	N	N	N	√	√	√	√	7
Sheraz (2019)	√	√	√	N	N	N	√	√	√	√	7
Fang et al. (2021)	√	√	√	N	N	N	√	?	N	√	5
Mei et al. (2009)	√	√	√	N	N	N	√	√	N	√	6
Ma et al. (2022)	√	√	√	N	N	N	√	√	√	√	7
Xiang et al. (2024)	√	√	√	N	N	N	√	√	√	√	7
He et al. (2020)	√	√	√	N	N	N	√	√	√	√	7
Ding et al. (2020)	√	√	√	N	N	N	√	√	√	√	7
Peng et al. (2022)	√	√	√	N	N	N	√	√	√	√	7
Liu et al. (2016)	√	√	√	N	N	N	√	√	√	√	7

(1) peer reviewed publication; (2) presence of randomization of subjects into treatment groups; (3) assessment of dose-response relationship; (4) blinded assessment of behavioural outcome; (5) monitoring of physiological parameters such as body temperature; (6) calculation of necessary sample size to achieve sufficient power; (7) statement of compliance with animal welfare regulations; (8) avoidance of anaesthetic agents with marked intrinsic neuroprotective properties (e.g., ketamine); (9) statement of potential conflict of interests; (10) use of a suitable animal model.

Abbreviations: √, fulfilling the criterion; N, not fulfilling the criterion; ?, not enough information to determine whether or not the criterion is fulfilled.